



ten23 health: Successful launch and strengthening of Board of Directors

- Dr. Ursula Redeker, a senior leader with a proven track record in the pharmaceutical and diagnostics industry, strengthens the Board of Directors.
- Integration of swissfillon, a leader in sterile filling of complex pharmaceuticals, is well on track.
- First customer contracts have been signed and the team has been strengthened with further industry experts.

Basel, November 29, 2021. ten23 health®, a global contract development and manufacturing organization (CDMO), announced today the addition of Dr. Ursula Redeker to its Board of Directors. Today ten23 health's Board of Directors consists of Prof. Dr. Hanns-Christian Mahler, CEO ten23 health, Nikhil Patel, Director, 3i Group and Richard Relyea, Partner 3i Group.

Dr. Redeker is a senior executive with a proven track record in the pharmaceutical and diagnostics industry. She brings experience from more than 15 years in various leadership roles at Roche Pharma including global head of Non-Clinical Safety & Technical Sciences, head Technical Development Biologics and 6 years as spokesperson of the Executive Board, Roche Diagnostics GmbH, Germany. She currently serves as a member of the Board of Directors of ABB AG, Germany, the board of Smart4Diagnostics GmbH and is a member of the Academics Advisory Council of the University of Heidelberg.

Strengthening our Board

Prof. Dr. Hanns-Christian Mahler, Chief Enabling Officer (CEO) of ten23 health, commented: «With the addition of Ursula Redeker, we are strengthening our Board of Directors significantly. Ursula brings a wealth of experience from her pharmaceutical and diagnostic leadership roles on an executive and board level with a background in large Pharma, but also from the translation of academic research into early stage development. She is a strong strategic leader with a track record in leading continuous change and in developing the best talent. She is going to contribute to our mission of “people first” and will be a role model, particularly for our aspiring female leaders.»

Successful launch

ten23 health, launched on September 1st 2021 in Basel, has got off to a successful start. Discussions with biotech startups and pharmaceutical companies over recent weeks have confirmed the significant unmet need in the development of pharmaceutical products of complex, novel modalities. These discussions have led to ten23 health's first contracts. Recruiting both locally and internationally, ten23 health has further strengthened its team with additional industry experts and scientists with diverse backgrounds and experience.

Furthermore, the company has enhanced its offering to clients by the integration of swissfillon, a leader in sterile filling of complex pharmaceuticals, based in Visp, Switzerland. ten23 health's new combination of pharmaceutical development services with clinical and commercial fill & finish services offers clients an end-to-end set of capabilities. The integration of swissfillon, which will continue to operate under its own brand, is well on track.

About ten23 health

ten23 health®, headquartered in Basel, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test tomorrow's medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatment options for patients. swissfillon, a leader in the sterile filling of complex pharmaceuticals into innovative containers and devices, is a wholly owned subsidiary.

ten23 health combines the latest scientific findings with our proven and tested world-class industry and regulatory expertise to forge new paths for supporting our clients. We provide our innovative services in a fair and sustainable manner, respecting people's health and the future of our planet. ten23 health is solidly financed through the long-term commitment by 3i Group, an internationally reputable equity partner.

About the company's name

The numeric value for the number of molecules in a sample of one mol is called Avogadro constant and equals $6.022 \cdot 10^{23}$. Gram quantities of material contain the incredible number of 10^{23} atoms, which was an important discovery to understand the composition of matter: The world is built from small units, and not a homogeneous mass.

About 3i Group

3i is an investment company with two complementary businesses, Private Equity and Infrastructure, specializing in core investment markets in Northern Europe and North America. 3i's Private Equity team provides investment solutions for growing companies, backing entrepreneurs and management teams of mid-market companies with an Enterprise Value typically between €100m – €500m. The company backs international growth plans, providing access to its network and expertise to accelerate the growth of companies across the consumer, industrial, healthcare and business and technology services industries.

Media contacts:

ten23 health: Daniel Piller, media@ten23.health; +41 79 341 36 78.

swissfillon: Richard Hayhurst / Janet Joy RHAp, richard@rhapr.eu; +44 77 11 82 15 27

3i Group: Kathryn van der Kroft, Kathryn.VanDerKroft@3i.com; +44 20 7975 3021